Talzenna(talazoparib)
Talzenna (talazoparib) is a small molecule pharmaceutical. Talazoparib was first approved as Talzenna on 2018-10-16. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 2 and poly [ADP-ribose] polymerase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Talzenna (discontinued: Talzenna)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| talzenna | New Drug Application | 2025-04-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TALAZOPARIB TOSYLATE, TALZENNA, PFIZER | |||
| 2026-06-20 | I-920 | ||
HCPCS
No data
Clinical
Clinical Trials
119 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 12 | 1 | — | 4 | 22 |
| Neoplasms | D009369 | — | C80 | 12 | 7 | 1 | — | — | 18 |
| Prostatic neoplasms | D011471 | — | C61 | 5 | 5 | 1 | — | 2 | 12 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 2 | 2 | — | — | 7 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 2 | 1 | 1 | — | — | 4 |
| Hereditary breast and ovarian cancer syndrome | D061325 | — | — | 1 | 1 | 1 | — | — | 3 |
| Brca2 genes | D024522 | — | — | — | 1 | 1 | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | 2 | 6 | — | — | — | 7 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 2 | 1 | — | — | 1 | 4 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 1 | — | — | — | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 1 | — | — | — | 3 |
| Small cell lung carcinoma | D055752 | — | — | 2 | 1 | — | — | — | 3 |
| Carcinoma | D002277 | — | C80.0 | — | 2 | — | — | — | 2 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 2 | — | — | — | 2 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | 1 | — | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | 1 | 1 | — | — | — | 2 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | — | 2 |
Show 20 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 3 | — | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 2 | — | — | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
| Serous cystadenocarcinoma | D018284 | — | — | 1 | — | — | — | — | 1 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Talazoparib |
| INN | talazoparib |
| Description | Talazoparib, sold under the brand name Talzenna, is an anti-cancer medication used for the treatment of breast cancer and prostrate cancer. It is an orally available poly ADP ribose polymerase PARP inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib.
|
| Classification | Small molecule |
| Drug class | poly-ADP-ribose polymerase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 1207454-56-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3137320 |
| ChEBI ID | — |
| PubChem CID | 135565082 |
| DrugBank | DB11760 |
| UNII ID | 9QHX048FRV (ChemIDplus, GSRS) |
Target
Agency Approved
PARP2
PARP2
PARP1
PARP1
Organism
Homo sapiens
Gene name
PARP2
Gene synonyms
ADPRT2, ADPRTL2
NCBI Gene ID
Protein name
poly [ADP-ribose] polymerase 2
Protein synonyms
ADP-ribosyltransferase (NAD+; poly(ADP-ribose) polymerase)-like 2, ADP-ribosyltransferase diphtheria toxin-like 2, ADPRT-2, ARTD2, DNA ADP-ribosyltransferase PARP2, hPARP-2, NAD(+) ADP-ribosyltransferase 2, pADPRT-2, poly (ADP-ribose) polymerase family, member 2, poly (ADP-ribosyl) transferase-like 2, Poly[ADP-ribose] synthase 2, poly[ADP-ribose] synthetase 2, Protein poly-ADP-ribosyltransferase PARP2
Uniprot ID
Mouse ortholog
Parp2 (11546)
poly [ADP-ribose] polymerase 2 (Q99N29)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,988 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,209 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use